Sélectionner une page

HERBAMIG – Migraine

Collaboration

This project is in collaboration with the INSERM research center on  facial pain and migraine: Neuro-Dol. As well as with the participation of the Rhone-Alpes-Auvergne region

HERBAMIG : New TRP inhibitor

 

HerbaMig is a new and innovative treatment to prevent migraine disorders. By targeting specific receptors (trpa1), it prevents the outbreak of the crisis.

The two clinical studies in humans, as well as in vivo and in vitro studies in chronic pain models, show similar results to propranolol, the most used preventive treatment in migraine. HerbaMig shows no toxicity and has no side effect. Made in GMP conditions the plants are dosed in active principles and we ensure a minimum quantity to guarantee the quality of our plants.

Currently marketed as a food supplement, HerbaMig has attracted scientists’ interest in these incredible faculties. Today, 2 laboratories INSERM (National Institute of Health and Medical Research) participate in the improvement and understanding of this specific combination of plants and vitamins.

Physiopathology:

Migraine is a complex neurological condition which affects 12% of the world’s population, characterized by frequent headaches that can last between 4 and 72 hours. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. In most cases, migraine is associated with symptoms such as photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances.

Current available treatment:

The current migraine treatment landscape is mainly dominated by generic drugs, as the majority of migraine drugs have seen their patents expire. Pharmacological treatment is commonly segmented into two groups, acute treatment: Sumatriptan (1990); Zomig (1997); Almogran (2002), and preventative treatment: Propranolol (Beta blocker, 1989); Topiramate (Ca++ antagonist, 1996); Effexor (antidepressant, 1998) etc. No new preventive treatment since 2005!

Current R&D pipeline:

Since the discovery of triptans in 1972, migraine treatment research is still concentrated on symptomatic treatments. Multiple chemical & biological drugs are under development, such as CGRP antagonists. Because the market potential is > US$ 10 billion /year all the pharma industries follow the same target. CGRP antagonists act to limit inflammation during the migraine attack. TRPA1 inhibitors are an ideal supplement because they prevent the onset of the seizure.

HerbaMIG a new TRPA1 channel blocker:

TRP channels are a large family discovered a short time ago. TRP-A1 is an ion channel located on the plasma membrane of many human cells. This ion channel is best known as a sensor for environmental irritants giving rise to somatosensory modalities such as pain, cold and itch. In migraine patients, the strong activation of TRPA1 will trigger a migraine attack. These channels are today the main target of scientific research, as they can contribute to the discovery of new treatments in multiple pathologies. Our studies show that the combination of active ingredients of plants in specific proportions can desensitize the TRPA1 receptor and thus limit the triggering of a migraine attack.

 

Herbamig desensitizes the TRPA1 receptor.
AITC : agonist trpa1
Electophysiological recording in a mouse model.

Herbamig VS propranolol

Injection of the inflammatory soup over the meninges at t0, evaluation of the pain in a murine model, by Von Frey filament over time.

Two clinical studies

 

Open study – Department of neurology CLERMONT-FERRAND (France)

12 migraine patients – 3 months treatment

Salix Alba + Tanacetum Parthenium (Vitrobio’s extraction & purification)

2006

Randomized, Double blind, Placebo, Clinical Trial– Mudra clincare Hospital (India)

150 migraine patients – 1 month baseline + 3 months treatment

Salix Alba + Tanacetum Parthenium (Vitrobio’s extraction & purification)

2019

[et_pb_posts_carousel_agsdcm _builder_version= »4.4.3″ hover_enabled= »0″][/et_pb_posts_carousel_agsdcm]

Next